Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy - Takeaways - MDSpire

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy

  • By

  • Xinwang Gong

  • Chang Zhou

  • Yutao Wu

  • May 1, 2026

  • 0 min

Share

  • 1

    Residual inflammatory risk (RIR) becomes the primary modifiable factor for recurrent major adverse cardiovascular events post-PCI.

  • 2

    High-sensitivity C-reactive protein (hsCRP) levels ≥2 mg/L at 1 month post-PCI predict increased risks of MACE and all-cause mortality.

  • 3

    Routine reassessment of hsCRP at 1 month post-PCI is suggested to identify patients who may benefit from targeted anti-inflammatory treatments.

  • 4

    Achieving both LDL-C <70 mg/dL and hsCRP <2 mg/L is proposed as a dual-target criterion for optimal secondary prevention.

  • 5

    Current guidelines lack systematic hsCRP reassessment, potentially missing over 40% of patients with persistent RIR.

Original Source(s)

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy

  • by Xinwang Gong, Chang Zhou, Yutao Wu

  • May 1, 2026

Related Content

MRI-based training model for left atrial appendage closure

Non-contrast-enhanced multiparametric cardiac magnetic resonance reveals coronary microvascular functional and structural obstruction after percutaneous coronary intervention

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.